Top Pharma news of the week India Infoline New s Service | Mumbai | December 03, 2010 17:35 IST BSE NSE
172.20 -0.30 (-0.17%) 172.35 -0.35(-0.20%)
Top Stories Natco to accept ANDA for genericversion of Oseltamivir Phosphate NatcoPharma Limited is pleased to announce the acceptance of its Abbreviated NewDrug Application for the generic version of Oseltamivir Phosphate capsules.Natco has tied up with Luxemburg based Alvogen IPCO S.a.r.l for marketing andsale of Oseltamivir Phosphate in the USA. Natco is the first applicantto file an ANDA for the generic version of Tamiflu and should the ANDA beapproved may be entitled to 180 days of generic market exclusivity. Glenmark announces positiveresults from Crofelemer study
Glenmarkannounces positive results from the multi-centre study of Crofelemer in acutewatery diarrhoea in adult patients. In this multi-centre, placebo controlledtrial, resolution of diarrhoea was significantly higher in the Crofelemer armcompared to placebo. The clinical success rate was also greater in theCrofelemer arm compared to placebo. Crofelemer was found to be safe with noapparent differences in adverse event profile in the Crofelemer group comparedto placebo. Thistrial in mild to moderate adult patients with acute watery diarrhoea was thesecond proof of concept study conducted by Glenmark with Crofelemer. Adultpatients with mild to moderate diarrhoea were dosed with Crofelemer over aperiod of 3 days with a follow-up period of 30 days. This was a 3 arm drug vsplacebo study which included a 125 mg, 250 mg and a 500 mg dose of Crofelemer.Overall Crofelemer showed superiority to the placebo arm. For the efficacy parameterof stool frequency, there was a significant difference in the reduction ofnumber of stools per day during 3 days of treatment period between both thelowest and highest Crofelemer doses versus Placebo. ReadMore AstraZeneca and Taj launchesGemcitabine HCI for Injection: report AstraZenecaPharmaceuticals and Taj Pharmaceuticals, have commercially launched GemcitabineHCI for Injection in 200 mg and 1 g single dose vials in the US. According to reports,Gemcitabine HCI for Injection, the generic version of Gemcitabine HCI, waslaunched pursuant to a commercialization, manufacture and supply agreementsigned by AstraZeneca and Taj Pharmaceuticals. As perthe agreement, AstraZeneca will manufacture Gemcitabine HCI for Injection andwill receive a license to market the product within the India-based firm's180-day exclusivity. Taj Pharma will get a royalty during the manufacturingperiod.
In Focus Stories Medwin HeartFoundation to host 3rd Edition of Prevent India program on Feb 19 Medwin Heart Foundation will host the 3rd Edition of Prevent India program in Hyderabad on February 19, 20th, 2011. In the3rd Edition of Prevent India 2011(www.preventindia.org)on Preventive Cardiologyto be held in Hyderabad, globally known cardiologists and medical practionerswill be deliberating the 'When and How' to control these risks especially inhypertension, hyperlipidaemia, smoking, diabetes mellitus, obesity andthrombogenicity including NCD ( Non Communicable Diseases) Prof. K Srinath Reddy, President Public Health Foundation ofIndia, Dr. Prabhakaran, Center for Chronic Disease Control, Executive Directorof Initiative for Cardiovascular Health Research, Dr. Ramesh Babu, MD, MedwinHeart Foundation and ideator of Prevent India, Dr. Mala Rao, President IndianInstitute of Public Health, Dr. Arun Chockalingham, Director, Office of GlobalHealth, NHLBI, NIH, USA and many other prominent doctors of repute will attendand address the 2 day program. ReadMore South Asian countriesface health crisis: World Bank A new World Bank report warns that South Asian countries arefacing a health crisis with rising rates of heart disease, diabetes, obesity,and other noncommunicable diseases (NCDs), which disproportionately affect poorfamilies, with possible side effects of disability and premature death, andworsening poverty as people pay for medical treatment out of their own pockets. According to the new report?Capitalizing on the DemographicTransition: Tackling Noncommunicable Diseases in South Asia?heart disease inthe region is now the leading cause of death in adults aged 15-69, and SouthAsians suffer their first heart attacks six years earlier than other groupsworldwide. ReadMore ASSOCHAMdemands lower tax rate for health care sector MickeyMehta teams up with milon to revolutionize Indian fitness culture IsYoga branding is a Service or Commercialisation of Yoga
Results PiramalHealthcare Q3 net profit dips 46% Piramal Healthcare Ltd has posted a net profit ofRs. 603.30 mn for the quarter ended December 31, 2010 where as the same was atRs. 1362.10 mn for the quarter ended December 31, 2009. Total Income is Rs.5348.80 mn for the quarter ended December 31, 2010 where as the same was at Rs.9239.40 mn for the quarter ended December 31, 2009. The figures for the quarter and nine months endedDecember 31, 2010 are not comparable to the previous quarter and nine monthsended December 31, 2009 on account of the sale of Domestic formulation businessand Diagnostics Services.
converted by Web2PDFConvert.com
SeQuentScientific Q3 net profit up 14% ElderPharma Q3 net profit up 3% AurobindoPharma Q3 net profit up 24%
DomesticNews
AnkurDrugs sets up facility at Himachal Pradesh
PanaceaBiotec launches PacliALL
U.S.Postal Inspection Service Awards AED Contract to Cardiac Science
Ciplais Most Trusted Brand in Pharmaceutical industry in India
OptoCircuits arm to deploy Powerheart AEDs at U.S Postal Inspection Service sites
VasanHealth Care to establish 28 eye care centers in East, West and North India
LincolnPharma introduces India's first Long-Acting Paracetamol 'Pa-12'
KohinoorHospital organizes funeral procession of cigatette
InternationalNews
Pfizer to acquire Ferrosan’s consumer healthcare business
Pfizer Inc. announced that it hasentered into a definitive agreement to purchase Ferrosan’s consumer healthcarebusiness, which includes dietary supplements and lifestyle products, from Altor2003 Fund GP Limited. Based in Copenhagen,Ferrosan is an innovative and long-established consumer healthcare company inthe Nordic region with a portfolio of leading brands. Since 1920, Ferrosan hasgrown to serve a broader market including Russia,the Ukraine, Poland, Turkeyand many countries throughout Central and Eastern Europe.ReadMore
Kindredto acquire RehabCare
Astellassigns antibiotic deal with Optimer: report
converted by Web2PDFConvert.com